Please login to the form below

Not currently logged in
Email:
Password:

MethylGene appoints Peggy Mulligan as director

Former chief financial officer at Valeant to join Canada-based biotech

Former chief financial officer of Valeant Pharmaceuticals Peggy Mulligan has joined the board of directors at Canada-based MethylGene.

Charles Grubsztajn, president and CEO of the small molecule drug development company, highlighted Mulligan's experience in finances and auditing as reasons for her appointment.

“We look forward to her guidance as we plan for the future,” he said.

Mulligan had previously been chief financial officer and executive VP at Biovail before its merger with Valeant in September 2010 in which she played a key role, co-leading the merger and subsequent integration between the two companies.

She resigned from Valeant in December 2010, just three months after the merger, to pursue other interests.

Prior to her time at Biovail/Valeant, Mulligan served as executive VP and chief financial officer and treasurer of Linamar Corporation from 2005 to 2007.

Previously, she spent eleven years in various roles at the Bank of Nova Scotia, most recently as executive VP, systems and operations.

In 2003 and 2004 Mulligan was also named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network.

21st March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...